Analysis of XXXX and @entity11249 production in @entity5072 and neoplastic @entity35 pituitary tissues by the hemolytic plaque assay.

@entity5 @entity5072 @entity4743 @entity11249 @entity4611 @entity3695 @entity977 @entity35 @entity4742
The reverse hemolytic plaque assay (RHPA) was used to detect hormone release from cultured normal, @entity5072 , and neoplastic @entity35 pituitary cells. @entity5072 pituitary cells were produced by s.c. @entity4742 ( @entity4743 ) treatment (10 mg in Silastic tubes) for 3, 6, and 9 weeks. Neoplastic pituitary cells from @entity35 with @entity5 treated with @entity4743 for 3 weeks were also analyzed. Aliquots of the same cells were also analyzed by immunocytochemical staining. @entity4743 treatment resulted in an increase in @entity3695 (PRL)-producing cells in @entity4611 compared to untreated pituitaries after 9 weeks of treatment by the RHPA [61.2 +/- 5.2 (SE) versus 32 +/- 3.0] and by immunocytochemical staining [70.9 +/- 2.4 versus 36 +/- 1.4]. The percentage of mammosomatotropic cells decreased from 11.3 +/- 3.8 to 4.2 +/- 2.6% in pituitary cells from these same groups of animals. After 3 weeks of @entity4743 treatment in @entity35 with @entity5 , there was an increase in @entity11249 ( @entity11249 )-producing cells and a decrease in PRL-producing cells when analyzed by the RHPA (control: percentage of @entity11249 , 36.3 +/- 6.2; percentage of PRL, 39.0 +/- 1.6 versus @entity4743 -treated @entity5 : percentage of @entity11249 of 68.2 +/- 1.9; and percentage of PRL, 3.2 +/- 1.8%). The percentage of mammosomatotropic cells declined from 12.4 +/- 2.3 to 0.77 +/- 2.4%. A combined procedure of RHPA followed by immunocytochemical staining on the same slides also revealed a decline in mammosomatotropic cells after chronic @entity4743 treatment in @entity5072 and neoplastic @entity5 cells. These results show that @entity4743 has different effects on PRL and @entity11249 secretion and storage in @entity5072 pituitary and in the MtT/W15 @entity977 cells.
